Special Edition: Reduction of Residual Risk in Cardiovascular Disease: Focus on Triglycerides
This special series of Diabetes Core Update is supported by an independent educational grant from Amarin Corp.
For more than 30 years, statins have been the cornerstone of lipid management to reduce the risk of cardiovascular disease (CVD) and heart-related events. These medications have been proven to effectively lower LDL cholesterol levels and CVD risk in a wide array of patient populations. But even after patients meet their LDL cholesterol goals, the risk for CVD-related events isn’t completely abolished—a significant “residual risk” remains in most populations.
In this special series made possible by an unrestricted educational grant from Amarin Corp, Diabetes Core Update will explore the concept of residual risk in CVD, while specifically discussing the role of triglycerides as a CVD risk factor and a target to reduce residual risk. Dr. Neil Skolnik is joined by Dr. Christie Ballantyne (Professor of Medicine-Cardiology and Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine) and Dr. Charles Vega (Clinical Professor of Family Medicine and Associate Dean in the School of Medicine at the University of California, Irvine) to discuss the concept of residual risk, reducing residual risk, how to optimize cardiovascular risk reduction and when to address various factors, the role of high triglycerides in relation to other risk factors, and common clinical cases and real-world challenges to optimally reduce CVD risk in various patient populations.
Please listen to each episode by clicking on the podcast players below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
November 11, 2024
Special Edition: Residual Risk–A Focus on Triglycerides: Part 1 Revisited
Play Episode
Total Time: 24:50 | File Size: 34.4 MB
In this special episode, our host, Dr. Neil Skolnik, discusses triglycerides and how to reduce residual risk in cardiovascular disease. He is joined by Dr. Christie Ballantyne, Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine.
This special episode is supported by an independent educational grant from Amarin.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health.
Christie Ballantyne, M.D., Professor Medicine-Cardiology, and Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine.
References and Related Resources:
Niacin: AIM-HIGH - N Engl J Med 2011; 365:2255-2267
Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280
Pemafibrate: PROMINENT - N Engl J Med 2022; 387:1923-1934
Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098
Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22
ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168
September 18, 2024
Special Edition: Lipids–Beyond Statins and LDL Cholesterol: Part 2
Play Episode
Total Time: 26:59 | File Size: 37.4 MB
Episode Notes
In this special episode, titled “Lipids–Beyond Statins and LDL Cholesterol,” our host, Dr. Neil Skolnik, will discuss with two expert guests the details of treatment for LDL-cholesterol, triglycerides, and other lipid risk markers.
This special episode is supported by an independent educational grant from Amarin.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health.
James Underberg, M.D., Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, Director of the Bellevue Hospital Lipid Clinic, and Past President of the National Lipid Association.
Layla A. Abushamat, M.D., MPH, Assistant Professor, Department of Medicine in the Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas.
References and Related Resources:
Icosapent Ethyl: REDUCE-IT: N Engl J Med 2019; 380:11-22
Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl: JACC. 2024 Apr, 83 (16) 1529–1539
Icosapent ethyl following acute coronary syndrome: European Heart Journal 2024; 45:1173–1176
Cardiovascular Disease and Risk Management: ADA Standards of Care in Diabetes—2024: Diabetes Care 2024;47(supp 1): S179–S218
June 19, 2024
Special Edition: A Focus on Triglycerides, Metabolic Syndrome: Part 1
Play Episode
Total Time: 30:38 | File Size: 42.0 MB
Episode Notes
In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Metabolic Syndrome: A Focus on Triglycerides with Dr. Peter Toth. Dr. Toth is Director of Preventive Cardiology, CGH Medical Center, and an adjunct professor of medicine at Johns Hopkins Medical School.
This special episode is supported by an independent educational grant from Amarin.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Peter Toth, M.D., PhD, Director of Preventive Cardiology, CGH Medical Center, Adjunct Professor of Medicine, Johns Hopkins Medical School.
References and Related Resources:
Icosapent Ethyl: REDUCE-IT: N Engl J Med 2019;380:11-22
Omega-3 Fatty Acids: STRENGTH trial - JAMA 2020;324(22):2268-2280
Pemafibrate: PROMINENT - N Engl J Med 2022;387:1923-1934
Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098
Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study: BMJMED 2024;3:e000451
November 9, 2023
Special Edition: Focus on Triglycerides, Reduction of Residual Risk in CVD: Part 2
Play Episode
Total Time: 28:08 | File Size: 39.0 MB
Episode Notes
In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Charles Vega, Clinical Professor of Family Medicine and Associate Dean in the School of Medicine at the University of California, Irvine.
This special episode is supported by an independent educational grant from Amarin.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Charles Vega, M.D., Clinical Professor of Family Medicine, Director, UC Irvine Program in Medical Education for the Latino Community, and Associate Dean in the School of Medicine at the University of California, Irvine.
References and Related Resources:
Icosapent Ethyl: REDUCE-IT: N Engl J Med 2019; 380:11-22
ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168
See Episode 1 for further references.
August 15, 2023
Special Edition: Focus on Triglycerides, Reduction of Residual Risk in CVD: Part 1
Play Episode
Total Time: 24:43 | File Size: 34.3 MB
Episode Notes
In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Christie Ballantyne, Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine.
This special episode is supported by an independent educational grant from Amarin.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Christie Ballantyne, M.D., Professor of Medicine-Cardiology, Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine.
References and Related Resources:
Niacin: AIM-HIGH - N Engl J Med 2011; 365:2255-2267
Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280
Pemafibrate: PROMINENT - N Engl J Med 2022; 387:1923-1934
Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098
Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22
ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168
Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals: Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Users can freely access previous episodes of Diabetes Core Update here.
For previous episodes, please visit:
